Apostolos Evangelidis, MD
Urology · Manhattan, KSNPI 1902909138
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,722 of the $4,167 with a category attached, or 89.3%. It is spread thinly across 41 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations.
Across 241 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$732
- AbbVie$571
- Johnson & Johnson$481
- Pfizer$383
- Axonics, Inc.$228
- Progenics Pharmaceuticals, Inc.$194
- plus $2K from 35 others
What the payments were for
- Food & beverage$3,72289%
- Education$44511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 42 | $732 |
| AbbVie(2 entities) | 48 | $571 |
| Johnson & Johnson | 21 | $481 |
| Pfizer | 21 | $383 |
| Axonics, Inc. | 16 | $228 |
| Progenics Pharmaceuticals, Inc. | 9 | $194 |
| Sumitomo Pharma America, Inc. | 11 | $184 |
| Boston Scientific | 6 | $131 |
| Healthtronics Stone Solutions, LLC | 1 | $125 |
| Endo Pharmaceuticals Inc. | 6 | $103 |
| Antares Pharma, Inc. | 6 | $88 |
| Urogen Pharma, Inc. | 4 | $80 |
| Blue Earth Diagnostics | 4 | $66 |
| Tolmar Pharmaceuticals, Inc. | 4 | $64 |
| Novartis | 3 | $59 |
| Teleflex LLC | 3 | $53 |
| Tolmar, Inc. | 2 | $50 |
| Urovant Sciences Inc | 3 | $47 |
| Procept Biorobotics Corporation | 2 | $42 |
| Travere Therapeutics, Inc. | 2 | $41 |
| Calyxo, Inc. | 2 | $40 |
| Myriad Genetic Laboratories, Inc. | 2 | $33 |
| Bayer | 2 | $32 |
| Ferring Pharmaceuticals Inc. | 2 | $32 |
| Coloplast | 2 | $28 |
| Olympus America Inc. | 2 | $28 |
| 180 Medical, Inc. | 1 | $28 |
| Melinta Therapeutics, LLC | 1 | $21 |
| Biotissue Holdings Inc. | 1 | $19 |
| Bard Access Systems, Inc. | 1 | $17 |
| AstraZeneca | 1 | $17 |
| BD | 1 | $17 |
| Valencia Technologies Corporation | 1 | $16 |
| Rochester Medical Corporation | 1 | $16 |
| Smith+Nephew | 1 | $16 |
| Dendreon Pharmaceuticals LLC | 1 | $15 |
| Neotract Inc. | 1 | $15 |
| Medtronic | 1 | $15 |
| Merck | 1 | $15 |
| Ambu Inc. | 1 | $14 |
| Laborie Medical Technologies Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,167 in reported general payments places this provider in the 65th percentile of 111 urology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 33 | $445,325 |
| MyrbetriqMirabegron | 196 | $114,901 |
| OrgovyxRelugolix | 21 | $54,696 |
| GemtesaVibegron | 62 | $39,154 |
| Abiraterone Acetate | 15 | $32,124 |
| Tamsulosin Hcl | 761 | $7,928 |
| Potassium Citrate ErPotassium Citrate | 55 | $7,402 |
| Solifenacin Succinate | 139 | $5,488 |
| WaterWater For Irrigation,sterile | 92 | $4,438 |
| Silodosin | 35 | $2,027 |
| Gentamicin Sulfate | 31 | $1,932 |
| Methenamine Hippurate | 57 | $1,879 |
| Testosterone Cypionate | 53 | $1,709 |
| Desmopressin Acetate | 36 | $1,576 |
| Tadalafil | 19 | $1,246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $732 | $560,226229 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $184 | $93,85083 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 111 urology providers in Kansas.
Other urology in Manhattan
- Felipe RossoManhattan$17K
- Kimberly KocourManhattan$7K
- Timothy RichardsonWichita$493K
- Wilson MolinaKansas City$239K
- Bristol WhilesKansas City$163K
- Jeffrey HolzbeierleinKansas City$78K
- Ahmad El-ArabiKansas City$55K
- David DucheneKansas City$33K
- Jason AnastOverland Park$31K
- Son NguyenMerriam$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.